Beijing Tiantan Biological Products(600161.SH) subsidiary obtains human coagulation factor IX clinical trial summary report

Beijing Tiantan Biological Products (600161.SH) announced that recently, "Human Coagulation Factor IX" developed by its subsidiary Chengdu Rongsheng Pharmaceutical Co., Ltd. ("Chengdu Rongsheng") has completed Phase III clinical trials and obtained the clinical trial summary report. It is reported that the clinical trial results of Human Coagulation Factor IX produced by Chengdu Rongsheng show that the main PK parameters of the drug are similar to the data of similar marketed products. After infusion, it can effectively increase the coagulation factor IX level in patients with hemophilia B, improve the coagulation function of patients with hemophilia B, and improve the bleeding symptoms and signs of patients with hemophilia B, and can effectively control bleeding in patients with hemophilia B. At the same time, the safety results show that this product has good safety in patients with hemophilia B during clinical application.